# Pfizer Candidate Shows Immune Response Across 25 Serotypes in Phase 2

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/40299
Published: 2026-10-24T20:11:56.000Z
Updated: 2026-10-24T20:11:56.000Z
Section: Business

> A four-dose series of PF-07872412 was evaluated, with safety and tolerability also reported.

Pfizer’s experimental pneumococcal vaccine candidate PF-07872412 produced an immune response to all 25 targeted serotypes in a Phase 2 study. The study evaluated a four-dose series.

PF-07872412 is a pediatric vaccine candidate. Safety and tolerability were also reported.